Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Rachel E. Haurwitz Ph.D. | Co-Founder, CEO, President & Director | 979.08k | -- | 1986 |
| Dr. Steven B. Kanner Ph.D. | Chief Scientific Officer | 669.31k | -- | 1959 |
| Ms. Barbara G. McClung Esq., J.D. | Chief Legal Officer & Corporate Secretary | 669.31k | -- | 1955 |
| Mr. Sriram Ryali M.B.A. | Chief Financial Officer | -- | -- | 1982 |
| Mr. Daniel Poon | Vice President of Operations & Information Technology | -- | -- | -- |
| Mr. Ryan Fischesser | Interim Principal Accounting Officer & Controller | -- | -- | -- |
| Mr. Timothy P. Kelly M.B.A. | Chief Technology Officer | -- | -- | 1969 |
| Ms. Amy Figueroa C.F.A. | Vice President of Investor Relations & Corporate Communications | -- | -- | -- |
| Ms. Reigin Zawadzki | Chief People Officer | -- | -- | -- |
| Ms. Ruhi A. Khan M.B.A. | Chief Business Officer | 573.9k | -- | 1975 |
Caribou Biosciences, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 158
Description
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available